Pharm-Olam recognized by 2020 CRO Leadership Awards second year in a row

Pharm-Olam LLC, is the winner of 5 Life Science Leader’s CRO leadership awards in 2020: Capabilities, Compatibility, Expertise, Quality, and Reliability. APRIL 29, 2020 HOUSTON, TX, April 29, 2020– Pharm-Olam, a leading mid-sized clinical research organization (CRO) serving the pharmaceutical and biotech industry, won multiple recognitions in Life Science Leader magazine’s 2020 CRO Leadership Awards. […]

Accredited Internationally Qualified Clinical Research Auditor Standard Launches

Launching May 4th, the clinical research Audit Academy blends virtual training and development facilitated by Pharm-Olam and accredited by IAOCR. APRIL 27, 2020 Collaboration between Pharm-Olam and IAOCR ensures “quality built in” audits Houston, Texas and Maidenhead, United Kingdom, 27 April 2020 – The first Independently Accredited Clinical Research Audit Academy is registering delegates for its […]

Pharm-Olam selected to support Revive Therapeutics development of Bucillamine for COVID-19

Revive Therapeutics Ltd. is pleased to announce that the Company has retained Pharm-Olam, LLC, as CRO to advance the future clinical study for Bucillamine in the treatment of coronavirus disease (“COVID-19”).  MARCH 26, 2020 TORONTO, March 25, 2020 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused […]

Pharm-Olam’s Response to COVID-19: Safety, Community, Research

Read Pharm-Olam’s response to COVID-19 as they continue their commitment of safety, community, and research. MARCH 23, 2020 The coronavirus (COVID-19) was recently declared a pandemic by the World Health Organization (WHO), and countries around the world are working to flatten their infection curve and forestall the transmission of this dangerous virus. At Pharm-Olam, we […]

COVID-19 CATO SMS OPERATIONS UPDATE

MARCH 16, 2020 As the COVID-19 pandemic spreads across the globe, CATO SMS continues to take steps to address the challenges in study conduct that may arise due to illness, quarantine and restricted travel of study participants, clinical investigators, clinical site staff, and monitoring personnel. The events are unprecedented. Our number one priority is the […]